Kaliki S, Shields CL, Shields JA. Uveal melanoma: estimating prognosis. Indian J Ophthalmol. 2015;63:93–102.

Article  PubMed  Google Scholar 

Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127:989–98.

Article  PubMed  Google Scholar 

Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:4651–9.

Article  PubMed  Google Scholar 

Stalhammar G. Forty-year prognosis after plaque brachytherapy of uveal melanoma. Sci Rep. 2020;10:11297.

Article  PubMed  Google Scholar 

COMS. The COMS randomized trial of Iodine 125 Brachytherapy for Choroidal Melanoma: V. Twelve-year mortality rates and prognostic factors: COMS Report No. 28. Arch Ophthalmol. 2006;124:1684–93.

Article  Google Scholar 

Stålhammar G, Herrspiegel C. Long-term relative survival in uveal melanoma: a systematic review and meta-analysis. Commun Med. 2022;2:1–9.

Article  Google Scholar 

Wisely CE, Hadziahmetovic M, Reem RE, Hade EM, Nag S, Davidorf FH, et al. Long-term visual acuity outcomes in patients with uveal melanoma treated with 125I episcleral OSU-Nag plaque brachytherapy. Brachytherapy. 2016;15:12–22.

Article  PubMed  Google Scholar 

Toutee A, Angi M, Dureau S, Levy-Gabriel C, Rouic LL, Dendale R, et al. Long-term visual outcomes for small uveal melanoma staged T1 Treated by Proton Beam Radiotherapy. Cancers. 2019;11:1–11.

Shields CL, Shields JA, Cater J, Gunduz K, Miyamoto C, Micaily B, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol. 2000;118:1219–28.

Article  CAS  PubMed  Google Scholar 

Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol. 2002;120:1665–71.

Article  PubMed  Google Scholar 

Shields CL, Dalvin LA, Chang M, Mazloumi M, Fortin P, McGarrey M, et al. Visual outcome at 4 years following plaque radiotherapy and prophylactic Intravitreal Bevacizumab (Every 4 months for 2 years) for uveal melanoma: comparison with nonrandomized historical control individuals. JAMA Ophthalmol. 2020;138:136–46.

Article  PubMed  Google Scholar 

Bergman L, Nilsson B, Lundell G, Lundell M, Seregard S. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population. Ophthalmology. 2005;112:834–40.

Article  PubMed  Google Scholar 

Seddon JM, Gragoudas ES, Polivogianis L, Hsieh CC, Egan KM, Goitein M, et al. Visual outcome after proton beam irradiation of uveal melanoma. Ophthalmology. 1986;93:666–74.

Article  CAS  PubMed  Google Scholar 

van Beek JGM, van Rij CM, Baart SJ, Yavuzyigitoglu S, Bergmann MJ, Paridaens D, et al. Fractionated stereotactic radiotherapy for uveal melanoma: Long-term outcome and control rates. Acta Ophthalmol. 2021;100:511–9.

Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001;108:348–66.

Article  CAS  PubMed  Google Scholar 

Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Visual acuity after Ruthenium(106) brachytherapy of choroidal melanomas. Int J Radiat Oncol Biol Phys. 2005;63:392–400.

Article  PubMed  Google Scholar 

Tamplin MR, Deng W, Garvin MK, Binkley EM, Hyer DE, Buatti JM, et al. Temporal relationship between visual field, retinal and microvascular pathology following 125I-Plaque Brachytherapy for uveal melanoma. Invest Ophthalmol Vis Sci. 2021;62:3.

Article  CAS  PubMed  Google Scholar 

Dalvin LA, Zhang Q, Hamershock RA, Chang M, Yu MD, Mashayekhi A, et al. Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients. Br J Ophthalmol. 2020;104:697–702.

Article  PubMed  Google Scholar 

COMS. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol. 1998;125:745–66.

Article  Google Scholar 

Schoenfield L. Uveal melanoma: A pathologist’s perspective and review of translational developments. Adv Anat Pathol. 2014;21:138–43.

Article  CAS  PubMed  Google Scholar 

Saornil MA, Egan KM, Gragoudas ES, Seddon JM, Walsh SM, Albert DM. Histopathology of proton beam-irradiated vs enucleated uveal melanomas. Arch Ophthalmol. 1992;110:1112–8.

Article  CAS  PubMed  Google Scholar 

McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender’s classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol. 1983;96:502–9.

Article  CAS  PubMed  Google Scholar 

Callender G, Campbell Wilder H, Ash J. Five hundred melanomas of the choroid and ciliary body followed five years or longer. Am J Ophthalmol. 1942;25:962–7.

Article  Google Scholar 

Callender G. Malignant melanotic tumors of the eye: a study of histologic types in 111 cases. Trans Am Acad Ophthalmol Otolaryngol. 1931;36:131–42.

Google Scholar 

Kivelä T, Simpson ER, Grossniklaus HE, Jager MJ, Singh AD, Caminal JM, et al. Uveal Melanoma. AJCC Cancer Staging Manual. 8 ed. Chicago: Springer; 2017. pp. 805–17.

Google Scholar 

Shields CL, Kaliki S, Furuta M, Fulco E, Alarcon C, Shields JA. American Joint Committee on Cancer Classification of Posterior Uveal Melanoma (Tumor size category) predicts prognosis in 7731 patients.(Report). Ophthalmology. 2013;120:2066.

Article  PubMed  Google Scholar 

Simpson ER, Gallie B, Saakyan S, Amiryan A, Finger PT, Chin KJ, et al. International validation of the American Joint Committee on Cancer’s 7th Edition Classification of Uveal Melanoma. JAMA Ophthalmol. 2015;133:376–83.

Article  Google Scholar 

Weinhaus RS, Seddon JM, Albert DM, Gragoudas ES, Robinson N. Prognostic factor study of survival after enucleation for juxtapapillary melanomas. Arch Ophthalmol. 1985;103:1673–7.

Article  CAS  PubMed  Google Scholar 

Lindegaard J, Isager P, Prause JU, Heegaard S. Optic nerve invasion of uveal melanoma: clinical characteristics and metastatic pattern. Invest Ophthalmol Vis Sci. 2006;47:3268–75.

Article  PubMed  Google Scholar 

Fili M, Astrahan M, Stalhammar G. Long-term outcomes after enucleation or plaque brachytherapy of choroidal melanomas touching the optic disc. Brachytherapy. 2021;20:1245–56.

Folberg R, Pe’Er J, Gruman LM, Woolson RF, Jeng G, Montague PR, et al. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: A matched case-control study. Hum Pathol. 1992;23:1298–305.

Article  CAS  PubMed  Google Scholar 

Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Hwang T, Woolson RF, Pe’er J, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100:1389–98.

Article  CAS  PubMed  Google Scholar 

Folberg R, Maniotis AJ. Vasculogenic mimicry. APMIS. 2004;112:508–25.

Article  PubMed  Google Scholar 

Gamel JW, McCurdy JB, McLean IW. A comparison of prognostic covariates for uveal melanoma. Investigative Ophthalmol Vis Sci. 1992;33:1919.

CAS  Google Scholar 

McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol. 1982;13:123.

Article  CAS  PubMed  Google Scholar 

McLean IW, Keefe KS, Burnier MN. Uveal melanoma. Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size. Ophthalmology. 1997;104:777–80.

Article  CAS  PubMed  Google Scholar 

Gamel JW, McLean IW, Foster WD, Zimmerman LE. Uveal melanomas: correlation of cytologic features with prognosis. Cancer. 1978;41:1897–901.

Article  CAS  PubMed  Google Scholar 

Zimmerman LE. Pathology and computed tomography. Ophthalmology. 1980;87:602–5.

Article  CAS  PubMed  Google Scholar 

Folberg R, Fleck M, Mehaffey MG, Meyer M, Bentler SE, Woolson RF, et al. Mapping the location of prognostically significant microcirculatory patterns in ciliary body and choroidal melanomas. Pathol Oncol Res. 1996;2:229–36.

Article  PubMed  Google Scholar 

Herrspiegel C, Kvanta A, Lardner E, Ramskold Cabaca L, Wells J, Bartuma K, et al. Nuclear expression of BAP-1 in transvitreal incisional biopsies and subsequent enucleation of eyes with posterior choroidal melanoma. Br J Ophthalmol. 2021;105:582–6.

Article  PubMed  Google Scholar 

Shields CL, Sioufi K, Srinivasan A, Di Nicola M, Masoomian B, Barna LE, et al. Visual outcome and millimeter incremental risk of metastasis in 1780 patients with small choroidal melanoma managed by plaque radiotherapy. JAMA Ophthalmol. 2018;136:1325–33.

Article  PubMed  Google Scholar 

Herrspiegel C, See TRO, Mendoza PR, Grossniklaus HE, Stalhammar G. Digital morphometry of tumor nuclei correlates to BAP-1 status, monosomy 3, gene expression class and survival in uveal melanoma. Exp Eye Res. 2020;193:107987.

Article  CAS  PubMed  Google Scholar 

See TRO, Stålhammar G, Phillips SS, Grossniklaus HE. BAP1 immunoreactivity correlates with gene expression class in uveal melanoma. Ocul Oncol Pathol. 2019;6:1–9.

Stålhammar G, See TRO, Phillips S, Seregard S, Grossniklaus HE. Digital image analysis of BAP-1 accurately predicts uveal melanoma metastasis. Transl Vis Sci Technol. 2019;8:11.